USANA Health Sciences Inc (USNA) Stock AnalysisUSNAStock AnalysisUSANA Health Sciences Inc

USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures nutritional supplements, functional foods and personal care products. Its segments include Core nutritional and Hiya direct-to-consumer. The Core nutritional segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the core nutritional channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, Foods, Personal care and Skincare, and All other. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

USANA Health Sciences Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $14.04, and the company reported a significant earnings miss with an adjusted EPS of -$0.07 compared to expectations of $0.43. Additionally, the forward P/E ratio is 12.55, indicating that the stock may not be undervalued despite its current low price, while the recent news highlights a 5.3% year-over-year revenue decline, which raises concerns about future growth.

2 analysts cover USNA: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.00.